BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial

Reuters12-18

Dec 17 (Reuters) - Immuneering Corp IMRX.O:

IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA
IMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026
IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028

Source text: ID:nGNX9y1Bcm

Further company coverage: IMRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592943915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592943915","market":"fut","top_or_hot":-1,"title":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> <span>IMRX.O</span>:</p><ul><li><p>IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA</p></li><li><p>IMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026</p></li><li><p>IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028</p></li></ul><p>Source text: <span>ID:nGNX9y1Bcm</span></p><p>Further company coverage: <span>IMRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> <span>IMRX.O</span>:</p><ul><li><p>IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA</p></li><li><p>IMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026</p></li><li><p>IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028</p></li></ul><p>Source text: <span>ID:nGNX9y1Bcm</span></p><p>Further company coverage: <span>IMRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:1","article_id":"2592943915","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592943915","pubTimestamp":1766005722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib TrialDec 17 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4539":"次新股","IMRX":"Immuneering Corp","BK4139":"生物科技"},"translate_title":"简介-3期Atebimetinib试验中首位患者给药的免疫工程进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":0.9},"content_text":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib TrialDec 17 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMAIMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028Source text: ID:nGNX9y1BcmFurther company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592943915","isCrawlerRequest":true}